

# 5/3/2021 Updates

Dr. Thorson, Gunnison Valley Family Physicians

Public Information Office

GUNNISON COUNTY

# Janssen/Johnson & Johnson Update

- ▶ As of 4/23/21 the FDA and the State of Colorado is reauthorizing the use of the Janssen (Johnson & Johnson) vaccine
- ▶ The CDC's Advisory Committee on Immunization Practices (ACIP) completed a review of the data on the Johnson & Johnson vaccine as it relates to the potential for thrombosis with thrombocytopenia syndrome (TTS)
  - ▶ This is a form of blood clot
  - ▶ It is very rare in relation to the administration of the Johnson & Johnson vaccine
  - ▶ But, it is a real consideration
- ▶ The ACIP voted 10-4 that the Johnson & Johnson vaccine be reintroduced without any limitations on use
- ▶ Benefits of thorough use of vaccine outweigh the risks

# Johnson & Johnson: What did the ACIP review?

- ▶ The ACIP reviewed available evidence of the connection between the J&J vaccine and two types of blood clots;
- ▶ Cerebral Venous Sinus Thrombosis (CVST)
  - ▶ Normal Incidence: **14.5–28.5** per million U.S population\*
- ▶ Heparin Induced Thrombocytopenia (HIT)
  - ▶ Normal Incidence: **23–45** per million total U.S. population\*
- ▶ Reviewed evidence of 15 cases of TTS (blood clots)
  - ▶ Over 7 million U.S. residents have received Janssen vaccine, as of April 13, 2021
- ▶ \*Statistics sourced from ACIP Presentations (Sara Oliver MD, MSPH, ACIP Meeting, April 23, 2021) & University of Minnesota Center for Infectious Disease Research and Policy (CIDRP)

# What was found?

- ▶ All 15 of the cases involved women
- ▶ All but 2 of whom were under the age of 50. Seven of the 16 cases were in women ages 30 to 39.
  - ▶ CDC was investigating fewer than 10 additional possible cases.
- ▶ Seven of the 15 cases were in obese women, and two women were taking oral contraceptives. None had blood clotting disorders.
- ▶ Of the 15 women, 3 died, 5 were recovered or recovering at home, and 7 remained hospitalized, including 4 in the intensive care unit.
- ▶ All women experienced symptom onset no sooner than 6 days post-vaccination, but no later than day 15, and all reported headache, fatigue, and abdominal pain.
- ▶ Using the data that have been collected the risk of TTS from the J&J vaccine would be 7 TTS cases per 1 million doses administered to women ages 18 to 49.
  - ▶ The risk for women older than 50 would be 0.9 per 1 million doses.

# Johnson & Johnson: Moving forward

- ▶ Johnson & Johnson authorization upheld for all populations
- ▶ Recommended to educate population and recipients about very rare side-effect of TTS
- ▶ Those who receive J&J should monitor for the following:
  - ▶ Onset of symptoms on day #6 or later: headache, especially severe headache; Nausea/Vomiting; Chills/Fever, Abdominal pain; Shortness of Breath; Leg Pain) typical post-vaccination reaction range (day 6-14)
    - ▶ Median date of TTS symptom onset 8 days post vaccination
  - ▶ If symptoms occur, seek immediate medical attention

# Vaccine Clinics and Walk-Ins

- ▶ Don't Wait, Walk-In for a first dose!
- ▶ Walk-in clinics available
- ▶ 5/6/21
  - ▶ Fred Field Center
  - ▶ 11:30am-1pm Johnson & Johnson
  - ▶ 4-6pm Pfizer & Moderna

# Vaccination Numbers Update

Total Doses  
Administered

17,603


Individuals Fully  
Vaccinated

8,580



# Gunnison County Cases

**Swab and Rapid Test Data (prior 30-days, updated nightly)**

*Testing, some involving significant delays. Test results are back-posted to the day the test result was received. Thus, results for a day may change as new results are received.*



# Clarification on statewide increase in infection amongst school age populations



# Works Cited

- ▶ <https://www.cidrap.umn.edu/news-perspective/2021/04/acip-opts-lift-pause-johnson-johnson-vaccine>
- ▶ <https://www.cdc.gov/vaccines/acip/meetings/slides-2021-04-23.html>